A Systematic Review of Flurbiprofen 8.75 mg Dose and Risk of Haemorrhagic Events
Oral non-steroidal anti-inflammatory drugs (NSAIDs) are known to be associated with an increased risk of bleeding. The NSAID, flurbiprofen, in the form of 8.75 mg lozenge or oromucosal spray is indicated for the symptomatic relief of sore throat. Despite the low dose as compared to alternative flurb...
Saved in:
Main Authors: | Sandeep Dhanda (Author), Alison Evans (Author), Debabrata Roy (Author), Vicki Osborne (Author), Adam Townsley (Author), Graça Coutinho (Author), Anuradha Kulasekaran (Author), Saad Shakir (Author) |
---|---|
Format: | Book |
Published: |
Frontiers Media S.A.,
2021-08-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
A systematic review of flurbiprofen 8.75 mg dose and risk of adverse events (excluding haemorrhagic) resulting from drug-drug interactions
by: Alison Evans, et al.
Published: (2024) -
Observational assessment of safety in seroquel (OASIS): a specialist cohort event monitoring (SCEM) study in England
by: Vicki Osborne, et al.
Published: (2020) -
What Is the Difference Between Observed Association and Causal Association, Signals and Evidence? Examples Related to COVID-19
by: Vicki Osborne, et al.
Published: (2021) -
Relationship between Pharmacokinetic Profile and Clinical Efficacy Data of Three Different Forms of Locally Applied Flurbiprofen in the Mouth/Throat
by: Vit Perlik, et al.
Published: (2023) -
ASPC2024.CongressAd(7.875x10.75)_PRINT.pdf
Published: (2024)